Pall intensifies Asia focus
Pall intensifies Asia focus
Pall Life Sciences has
evolved from being a filtration and purification products vendor to
becoming a complete solution provider to life sciences companies. As
part of its growth strategy, Pall is investing significant resources in
expanding its operations in Asia
Pall Life Sciences has been active in the Asian market for over two
decades. The company’s approach is in line with its
corporate vision to serve the biopharmaceutical market as a
‘Total Solution Provider’, which is aligned towards
its ‘Total Fluid Management’ concept. The US-based
Pall Corporation recognizes Asia Pacific as high growth market, and is
consistently experiencing double digit growth in this region. Over the
last two years, it has made significant investments and restructured
its business to better support customers in the changing business
environment in Asia.
Two major steps in this direction were—the company understood
the requirements of direct engagement with customers, and acted by
coming out of the joint venture (JV) model. It established wholly-owned
direct subsidiaries and/or facilities in India, China, and Singapore.
As part of its growth strategy, Pall started fully-integrated Pall
Centers of Excellence in China and India, offering a range of services
to customers in process development and optimization.
Confirms Eric Garnier, president, Asia Pacific, Pall Life Sciences,
“Today’s sales are especially important for what
they portend for the future. Asia is a crucible where our new
products and selling strategies are tested. It is in these countries
that our global customers are building new plants and selecting their
filtration partners for their newest and most enduring
Products, applications and geographic diversity are among the
company’s greatest assets and a potent competitive advantage.
This diversity helps Pall to insulate itself from the natural rhythms
of markets. It served well in fiscal 2009, allowing the company to grow
revenues to nine percent for life sciences market in Asia as reported,
despite challenges in two key markets—the US and Europe.
Nearly 70 percent of Pall’s business is outside the US, with
more focus on Asian markets.
India is a very important region for Pall’s continuing
growth, and plays a major role for its success in the Asia region. The
company started Center of Exellence (CoE) in Bangalore in 2007 to
address the increasing demands of the Indian biopharmaceutical
industry. Today, it claims of having the most versatile support and
services group in India for filtration and bioprocess development using
“Our India CoE has two support groups that addresses
diversified biopharmaceutical needs. The Protein Applications
Development (PAD) group works on key aspects of protein purification.
Our PAD laboratory is equipped with the most modern equipment in
chromatography and mass spectroscopy,” shares Holly Haughney,
VP, Strategy and Business Development, Pall Life Sciences. The number
of filter validation conducted at the India CoE has grown by over 50
percent in the last two years, and it is expected to double its
customer base this year.
The services provided from Pall CoE in India, and other Asian countries
have been very critical for its accelerated growth in the APAC region.
The CoEs have enabled the company to work more closely with its
customers to help them optimize their processes and provide them most
advanced filtration and purification solutions in the speediest way.
Pall is running few manufacturing plants in Asia, and has chosen to
retain those that are most efficient, located closest to customers and
in lower cost regions. Currently, it has manufacturing bases in China
and India. The Pall Advanced Separation Systems (PASS) facility in Pune
manufactures standard as well as custom designed filtration, separation
and chromatography systems. The facility has the capability to
manufacture automated, semi-automated and manual direct flow filtration
systems, tangential flow filtration systems and chromatographic
systems. The facility in India also supports other Asian markets need.
As the number of drugs in the FDA approval process increases, so does
Pall’s sales of biopharmaceutical products and
systems. The biotechnology sector continues to be the major growth
engine for Pall with increasing number of biotech medicines
and vaccines entering development phase each year. The
company’s broad capability in the life sciences industry is a
competitive strength and an important element of its strategy going
forward. The company registered a sale of $389.9 million (about Rs
1,837 crore) in medical devices, and $550.6 million (about Rs 2,593
crore) from biopharmaceutical business in 2009.
The other factor driving Pall’s growth is increasing adoption
of its single-use processing systems to produce drugs.
“Disposables are an increasingly critical production
component for the fast growing areas of monoclonal antibody, genetic
medicine, protein therapeutics and vaccine manufacturing. Pall is a
pioneer in the development of single use technologies and has amongst
the broadest product portfolio,” says Ken Frank,
corporate vice president, Biopharmaceuticals Divison, Pall Life
Sciences. The company has supplied single-use technologies for many
years including self-contained filter capsules as an alternative to
stainless steel filter housings. Its Allegro single-use disposable
systems is increasingly popular, and offers many
advantages, including more flexible use of space and speed in
setting up of a new production line. Critical to the industry, they
also can reduce or eliminate the need for cleaning and cleaning
validation, and minimized the risk of cross-contamination between
batches and products.
Addressing the pandemic
The development and production of vaccines to combat influenza among
other diseases is an exploding market, believes Frank. Pall has a long
history of working closely with major vaccine manufacturers,
both in India and worldwide. It has established several process
solutions in flu vaccine manufacturing, both for traditional egg-based
processes and newer biotech-based cell culture processes. Pall is
working closely with those companies working on H1N1 influenza (swine
flu) vaccine in Asia and globally, by offering technologies and
solutions from the initial clarification stage with its Stax disposable
depth filters through concentration, with its wide range of tangential
flow microfiltration, ultra filtration cassette and hollow
fiber filter systems.
Says Frank, “Pall products including our Biosepra
chromatographic sorbents, Mustang membrane adsorbers, and our Allegro
Single Use Systems (SUS) featuring Kleenpak filter capsules, Allegro
biocontainers and the Kleenpak sterile connector, which is a market
leader in sterile connections, are all critical to vaccine
He further adds, “Our single use systems technologies have a
very important role to play in speeding up H1N1 vaccine development
which is absolutely crucial in the race for a solution to the current
flu pandemic, Pall has the products and knowledge to help customers
develop their products quickly, safely and economically.”
Thus, with the focus on China, India, Singapore and Korea, including
customers working on solutions to emerging pandemic threats, Pall will
continue investing in technologies, talents and state-of-art facilities
to provide its APAC customers with solutions to their expanding needs.